AURA Jul 2024 7.500 put
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 0.0000 |
| Ask | 2.8000 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
ZacksWall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High?
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 162.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GlobeNewswireAura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 12:30 p.m. ET. The live webcast of the presentation will be available on the “Investors & Media” pa
- GlobeNewswire
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will host a virtual KOL event on Wednesday, May 29, 2024 at 2:00 PM ET. To register, click here. The event will feature Carol Shields, MD (Wills Eye Hospital), Hakan Demirci, MD (University of Michigan), and Mandeep Sagoo, MB, PhD, FRCS (
